Tenderwize
Retour à la recherche

Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2027 · 429 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Brimonidin (amtlicher ATC-Code: S01EC24)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...

The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for Brinzolamid/Brimonidin.
  • Open-House model: any interested company may join during the participation period if it meets and accepts the conditions.
Afficher le résumé complet

This is an Open-House pharmaceutical supply arrangement for the active substance Brinzolamid/Brimonidin (ATC S01EC24) with AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation is handled electronically via DTVP, but submission is not via the bidder tool; the participation documents must be obtained from the project room after access approval. The notice is highly document-dependent, but the extracted procurement documents are not available beyond the XML notice text, so some submission details remain incomplete.

Risques

The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...

The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must declare no mandatory or discretionary exclusion grounds using the provided self-declaration form.

Administrative

  • A declaration regarding Russia sanctions compliance is required using the specified form.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin

Non-exclusive supply/framework-style Open-House agreement for pharmaceutical products containing Brinzolamid/Brimonidin (ATC S01EC24). Scope is the conclusion of rebate agreements with all eligible pharmaceutical companies. Place of performance is Dresden, Germany, with performance also linked to Saxony and Thuringia as stated in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Oct 31, 2027

Détails de la procédure

Date de publication
24 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
551011-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30